Neoadjuvant immunotherapy has the potential to decrease the risk of hepatocellular carcinoma (HCC) recurrence post resection. The objectives of this study were to assess the value of pre-treatment MRI parameters for prediction of HCC immunophenotype and response in a cohort of patients undergoing neoadjuvant immunotherapy prior to liver resection. We hypothesize that diffusion and perfusion MRI can predict HCC response to neoadjuvant immunotherapy. It was observed that abundant of TILs decreases ADC in tumors. Moreover, uptake rate is higher in highly necrotic tumors.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords